UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

  

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 29, 2016

 

  

TELIGENT, INC.

(Exact name of registrant as specified in its charter)

 

Delaware		001-08568		01-0355758
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

105 Lincoln Avenue
Buena, New Jersey 08310
(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (856) 697-1441

  

 

 

 

 (Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

   

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(d) Effective March 29, 2016, the Board of Directors (the “Board”) of Teligent, Inc. (the “Company”) approved the appointment of Carole S. Ben-Maimon, M.D., to serve as a member of the Board. Dr. Ben-Maimon has also been appointed to serve as a member of the Company’s Organization and Compensation Committee and Nominating and Corporate Governance Committee of the Board.

 

There are no arrangements or understandings between Dr. Ben-Maimon and any other person pursuant to which Dr. Ben-Maimon was appointed as a director. There are no transactions to which the Company is a party and in which Dr. Ben-Maimon has a material interest that is required to be disclosed under Item 404(a) of Regulation S-K.

 

Dr. Ben-Maimon will be compensated for her service on the Board in accordance with the Company’s director compensation policy and will be reimbursed for reasonable expenses incurred in connection with her service on the Board. In addition, the Company will enter into its standard form of director and officer indemnification agreement with Dr. Ben-Maimon.

 

Item 8.01 Other Events.

 

The Company issued a press release in connection with the appointment of Dr. Ben-Maimon to the Board. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number		Description
99.1		Press release of Teligent, Inc. dated March 31, 2016.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	TELIGENT, INC.
	By:	/s/ Jenniffer Collins
	Name:	Jenniffer Collins
	Title:	Chief Financial Officer

 

Date: March 31, 2016